myelodysplastic syndromes (MDS) | Page 156 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop

Author(s): 
Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D
Primary Author: 
Platzbecker U
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

Several new treatments for

Bone Marrow Disease(s): 

The long term risk of myelodysplastic syndromes among anemia patients: A population-based study.

Author(s): 
Meytes D, Chodick G, Shalev V, Porath A
Primary Author: 
Meytes D
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

We have utilized the computerized data of a nationwide health plan to elucidate several epidemiologic aspects and risk factor of

Bone Marrow Disease(s): 

Histone methylation in myelodysplastic syndromes

Author(s): 
Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G.
Primary Author: 
Wei Y
Journal Title: 
Epigenomics
Original Publication Date: 
Apr 2011

Histone methylation is a type of epigenetic modification that is critical for the regulation of gene expression. Numerous studies have demonstrated that abnormalities of this newly characterized epigenetic modification are involved in the development of multiple diseases, including cancer. There is also emerging evidence for a link between histone methylation and the pathogenesis of myeloid neoplasms, including

Bone Marrow Disease(s): 

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Author(s): 
Weiss Smith S, Sato M, Gore SD, Baer MR, Ke X, McNally D, Davidoff A
Primary Author: 
Weiss Smith S
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2011

Background. There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents.

Bone Marrow Disease(s): 

Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

Author(s): 
Sockel K, Ehninger G, Hofbauer LC, Platzbecker U
Primary Author: 
Sockel K
Journal Title: 
Expert Rev Hematol
Original Publication Date: 
Dec 2011

Allogeneic hematopoietic stem cell transplantation is still the only potentially curative treatment for patients with

Bone Marrow Disease(s): 
Share with addtoany.com.